Conditions: Disease, Hodgkin
Keywords: Antigens, CD30 Antibody-Drug Conjugate Antibodies, Monoclonal Disease, Hodgkin Hematologic Diseases Lymphoma monomethylauristatin E Drug Therapy Immunotherapy
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 102
Healthy volunteers: no

Brief summary:
This is a single-arm, open-label, multicenter, pivotal clinical trial to evaluate the efficacy and safety of brentuximab vedotin (SGN-35) as a single agent in patients with relapsed or refractory Hodgkin lymphoma.

Detailed description:

Arms:
arm 1: None

Interventions: intervention 1: brentuximab vedotin
Intervention descriptions: intervention 1: 1.8 mg/kg every 3 weeks by intravenous infusion

Protocol document: